By Counterforce Health Team in Poteligeo (mogamulizumab-kpkc) — 29 Oct 2025

Cigna's Coverage Criteria for Poteligeo (mogamulizumab-kpkc) in Illinois: What Counts as "Medically Necessary"?

Answer Box: Getting Poteligeo Covered by Cigna in Illinois

Cigna requires prior authorization for Poteligeo (mogamulizumab-kpkc) with three key criteria: (1) confirmed mycosis fungoides or Sézary syndrome with TNMB staging, (2) failure of at least one prior systemic therapy, and (3) prescription by an oncologist or dermatologist. First step today: Have your specialist submit a prior authorization request through Cigna's provider portal with complete TNMB staging documentation and prior therapy records. If denied, you have 180 days to file an internal appeal, followed by Illinois's external review process within 4 months of final denial.

Policy Overview
Indication Requirements
Step Therapy & Exceptions
Required Diagnostics
Site of Care Requirements
Evidence to Support Medical Necessity
Appeals Playbook for Illinois
Common Denial Reasons & Solutions
FAQ

Policy Overview

Cigna manages specialty drugs like Poteligeo through Express Scripts/Accredo specialty pharmacy with mandatory prior authorization across all plan types—commercial PPO, HMO, and Medicare Advantage. The policy applies uniformly whether you're enrolled in an employer plan or individual marketplace coverage in Illinois.

Key Policy Points:

Prior authorization required: All Poteligeo prescriptions must be pre-approved
Specialty pharmacy routing: Dispensed through Accredo or approved specialty pharmacy
Review timeline: 72 hours for standard requests, 24 hours for expedited
Appeal rights: 180-day window for internal appeals, followed by Illinois external review

Note: Cigna's 2024 Medicare Advantage plans may not require prior authorization for medical oncology use specifically, but commercial plans maintain PA requirements.

Indication Requirements

FDA-Approved Indications

Poteligeo is FDA-approved for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. Cigna's medical necessity criteria align directly with this FDA labeling.

Required Documentation:

Pathology report confirming cutaneous T-cell lymphoma (CTCL) diagnosis
Specific subtype identification (mycosis fungoides vs. Sézary syndrome)
Complete TNMB staging per ISCL/EORTC guidelines
Evidence of relapsed or refractory disease

Coverage at a Glance

Requirement	What It Means	Documentation Needed	Source
Prior Authorization	Pre-approval required	PA form via provider portal	Cigna PA Requirements
CTCL Diagnosis	MF or SS confirmed	Pathology report, staging	FDA Label
Prior Systemic Therapy	≥1 failed treatment	Treatment history, response	Clinical Guidelines
Specialist Oversight	Oncology/dermatology	Prescriber credentials	Cigna Policy
Site of Care	Non-hospital preferred	Infusion center approval	Express Scripts

Step Therapy & Exceptions

Required Prior Therapies

Cigna requires documentation of failure, intolerance, or contraindication to at least one prior systemic therapy. Skin-directed therapies alone do not qualify—the patient must have tried systemic treatment.

Qualifying Prior Systemic Therapies:

Methotrexate
Bexarotene (Targretin)
Interferon-alpha
HDAC inhibitors (vorinostat, romidepsin)
Systemic chemotherapy regimens
Other immunomodulatory agents

Medical Exception Pathways

If standard step therapy requirements pose clinical risks, document:

Contraindications: Specific medical reasons why typical first-line agents are inappropriate
Intolerance history: Previous adverse reactions with supporting clinical notes
Disease severity: Rapid progression requiring immediate targeted therapy

Tip: Include specific dates, dosages, and clinical outcomes for all prior therapies to strengthen your case.

Required Diagnostics

TNMB Staging Documentation

Complete staging using the ISCL/EORTC/USCLC TNMB classification system is essential for approval:

T (Skin): Clinical assessment of body surface area involvement, tumor presence

T1: <10% skin involvement
T2: ≥10% skin involvement
T3: Tumors present
T4: Erythroderma

N (Lymph Nodes): Physical exam, imaging if abnormal nodes detected

Biopsy required for suspicious lymphadenopathy

M (Visceral): Imaging studies if clinical suspicion of organ involvement

CT or PET imaging for advanced disease evaluation

B (Blood): Flow cytometry and Sézary cell counts for Sézary syndrome

B0: <250 Sézary cells/μL
B1: 250-1000 Sézary cells/μL
B2: >1000 Sézary cells/μL

Laboratory Requirements

Complete blood count with differential
Comprehensive metabolic panel
Flow cytometry (for Sézary syndrome)
TCR gene rearrangement studies if indicated

Site of Care Requirements

Cigna typically requires Poteligeo infusions to be administered in cost-effective settings outside of hospital outpatient departments, unless medically necessary.

Approved Infusion Sites:

Physician office infusion suites
Freestanding infusion centers
Ambulatory surgery centers
Home infusion (with appropriate monitoring)

Hospital Exception Criteria:

Complex medical comorbidities requiring hospital-level monitoring
High risk for severe infusion reactions
Lack of appropriate alternative infusion facilities in your area

Specialist Oversight Requirement

All Poteligeo prescriptions must be initiated and supervised by a board-certified oncologist or dermatologist with CTCL experience. This requirement cannot be waived and applies throughout the treatment course.

Evidence to Support Medical Necessity

Clinical Documentation Checklist

Your oncologist or dermatologist should include:

Diagnosis confirmation: Pathology reports, immunohistochemistry results
Staging documentation: Complete TNMB assessment with supporting studies
Prior therapy history: Detailed record of systemic treatments tried, responses, and reasons for discontinuation
Treatment rationale: Clinical justification for Poteligeo specifically
Monitoring plan: Schedule for response assessment and safety monitoring

Supporting Literature

Key references to strengthen medical necessity arguments:

FDA prescribing information for Poteligeo
NCCN Guidelines for T-Cell Lymphomas
MAVORIC trial data (pivotal Phase III study)
ISCL/EORTC consensus recommendations

From Our Advocates: "We've seen the strongest approvals when specialists include photographs documenting skin involvement, detailed flow cytometry reports for Sézary syndrome cases, and specific quotes from NCCN guidelines supporting Poteligeo use after documented systemic therapy failures. This comprehensive approach addresses Cigna's medical directors' key concerns upfront."

Appeals Playbook for Illinois

Internal Appeal Process

Level 1 - Standard Internal Appeal

Timeline: File within 180 days of denial
Response time: 15 business days for pre-service requests
How to file: Written request via Cigna member portal or mail
Required documents: Original denial letter, additional clinical documentation, prescriber letter

Level 2 - Peer-to-Peer Review

Process: Request direct physician-to-physician discussion
Timeline: Can be requested alongside or after Level 1 appeal
Contact: Call Cigna provider services with case reference number
Preparation: Have specialist prepare clinical summary and guidelines citations

Illinois External Review Process

If Cigna upholds the denial after internal appeals, Illinois residents can request an independent external review under the Health Carrier External Review Act.

External Review Timeline:

Filing deadline: Within 4 months of final internal denial
IRO assignment: Within 5 business days
Decision timeline: 30 days standard, 72 hours expedited
Cost: Free to consumers (insurers pay IRO fees)

How to File:

Contact Illinois Department of Insurance OCHI at (877) 527-9431
Complete external review application
Submit clinical records and denial documentation
Independent physician reviewer (board-certified in relevant specialty) makes binding decision

When to Request Expedited Review

Delay would seriously jeopardize health or ability to regain maximum function
Standard timeline would subject you to severe pain
Physician certifies urgent medical need

Common Denial Reasons & Solutions

Denial Reason	Solution	Required Documentation
"Incomplete staging"	Submit full TNMB assessment	Pathology, imaging, flow cytometry reports
"Insufficient prior therapy"	Document systemic treatment failures	Treatment timeline, response assessments, discontinuation reasons
"Not prescribed by specialist"	Transfer care or obtain consultation	Oncology/dermatology referral and treatment plan
"Experimental/investigational"	Cite FDA approval and guidelines	FDA label, NCCN recommendations, peer-reviewed studies
"Site of care not approved"	Request medical exception or change venue	Clinical justification for hospital vs. office setting

Sample Medical Necessity Letter Template

"[Patient] is a [age]-year-old with biopsy-confirmed [mycosis fungoides/Sézary syndrome] staged as [TNMB stage] per ISCL/EORTC criteria. Previous systemic therapies include [specific agents, dates, responses]. Current disease status shows [progression/refractory disease] with [clinical findings]. Poteligeo (mogamulizumab-kpkc) is FDA-approved for this indication and recommended by NCCN guidelines as appropriate therapy after prior systemic treatment failure. The patient meets all coverage criteria and requires this targeted therapy to achieve disease control."

FAQ

How long does Cigna prior authorization take for Poteligeo in Illinois? Standard review is 72 hours after Cigna receives all required documentation. Expedited reviews are completed within 24 hours for urgent cases.

What if Poteligeo is not on Cigna's formulary? You can request a formulary exception with clinical justification. This requires demonstrating medical necessity and may involve trying preferred alternatives first unless contraindicated.

Can I appeal if I live in Illinois but have coverage from another state? Illinois appeal rights apply to all residents regardless of where their insurance plan is based. You can use Illinois's external review process after exhausting internal appeals.

Does step therapy apply if I failed treatments outside of Illinois? Yes, prior therapy documentation from any location counts toward meeting step therapy requirements, as long as you have adequate records of treatment and response.

How much does Poteligeo cost with Cigna coverage? Costs vary by plan design. After prior authorization approval, you'll typically pay your plan's specialty drug copay or coinsurance. The manufacturer offers copay assistance programs that may reduce out-of-pocket costs.

What happens if my appeal is denied? After exhausting Cigna's internal appeals, you can file for external review through the Illinois Department of Insurance. This independent review is binding if decided in your favor.

About Coverage Appeals

Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into successful appeals by analyzing denial letters, plan policies, and clinical notes to craft targeted, evidence-backed rebuttals. The platform identifies specific denial reasons and drafts point-by-point responses aligned with each payer's own coverage rules, pulling appropriate medical evidence and weaving it into appeals that meet procedural requirements while tracking deadlines and required documentation.

For additional support with Poteligeo appeals in Illinois, Counterforce Health provides templates and guidance that can help streamline the prior authorization and appeals process, ensuring all necessary clinical facts and evidence citations are properly formatted for Cigna's review process.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies vary by plan and are subject to change. Always consult with your healthcare provider and review your specific insurance policy documents. For personalized assistance with insurance appeals in Illinois, contact the Illinois Department of Insurance Office of Consumer Health Insurance at (877) 527-9431.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.

Table of Contents